In 1966, Kimishige and Teruko Ishizaka [1] were the first to precipitate and characterize 'reaginic antibodies' from sera of atopic patients. As the newly identified antibody was different from the four immunoglobulin isotypes known at that time, it was designated IgE. Interestingly, preabsorption of serum from ragweed allergic patients with 'anti-γE' serum raised in rabbits abolished the passive skin sensitizing activity of the serum as measured by the Prausnitz-Kuestner reaction. Thus IgE and its link to allergy were discovered.
Already in the aforementioned study, IgE-specific antibodies raised in animals were used to block the effects of IgE in experimental settings. However, it took more than 2 decades until Presta et al. [2] at Genentech developed the first humanized IgG1 antibody directed against IgE and intended for therapeutic usage in 1993. This antibody, rhuMAb-E25, also called omalizumab, was designed to bind to the Cε3 region of free IgE and thus block the binding of IgE to the FcεRI present on mast cells and basophils. It decreases serum levels of free IgE by more than 95%. From a clinical point of view, therapy with omalizumab reduces asthma exacerbations and the use of rescue medication in adults and children suffering from allergic asthma.
Interestingly, already in the first clinical studies with omalizumab, an increase in total IgE levels accompanying 70 the beginning of the study, indicating that they had already functional allergen-specific IgE antibodies but that their levels were below the cut-off level of 0.35 kU/l. As the blood from 3 of the 4 patients was taken outside of the season, seasonal boost alone cannot explain the sudden detection of relevant IgE levels. It seems, therefore, that the polyclonal rise in IgE upon omalizumab therapy elevated the levels of allergenic-specific IgE that was already present -albeit at very low levels -beyond the cut-off point of 0.35 kU/l and made them 'detectable'.
One common explanation for the rise in IgE levels upon omalizumab therapy is that the relatively short halflife of free serum IgE (2-3 days) may be prolonged by binding to omalizumab, which belongs to the IgG1 subclass and has a half-life of approximately 26 days. However, there is also another potential explanation: Omalizumab may cross-link IgE present on the surface of IgEpositive memory B cells as B cell receptors by binding to its Cε3-free regions [6, 7] . These memory cells could be thereby activated, resulting in enhanced IgE production and total serum IgE levels. Though this current study contributes another piece to the jigsaw of understanding the rise in total IgE levels upon omalizumab therapy by showing it to be of polyclonal character, the issue regarding the underlying mechanism leading to the observed IgE rise remains unaddressed and awaits further investigation.
